Abstract:The c-Jun NH 2 -terminal protein kinase (JNK) pathway has been implicated in mammary tumor development. However, the molecular mechanisms regulating JNK activity in breast cancer cells remain unclear. Here, we report that the inhibition of ubiquitination-like post-translational modification neddylation through different strategies results in enhanced basal JNK phosphorylation in human breast cancer cells. The upregulation of basal JNK phosphorylation upon neddylation inhibition is independent of the deneddylation of Cullins, the well-characterized neddylation substrates. Since augmented basal JNK phosphorylation via ectopic MKK7 expression impedes proliferation and the epithelial-to-mesenchymal transition (EMT) phenotype, the neddylation system might contribute to mammary tumor development partially through limiting basal JNK phosphorylation. Further exploration reveals that MKK7, a JNK-specific MAP2K, undergoes neddylation in human breast cancer cells. MKK7 co-precipitates with a fragment of Ran-binding protein 2 (RanBP2), a large multimodular and pleiotropic protein that has been recognized as a SUMO E3 ligase. Knockdown of RanBP2 attenuates MKK7 neddylation and augments basal JNK phosphorylation without affecting the neddylation of Cullins, whereas ectopic expression of a RanBP2 fragment possessing SUMO E3 activity (RanBP2ΔFG) manifests the opposite effects. In vitro neddylation assays confirm that RanBP2ΔFG works as the neddylation E3 ligase for MKK7. The basal kinase activity of endogenous MKK7 increases upon RanBP2 knockdown but decreases upon the ectopic expression of RanBP2ΔFG. Furthermore, purified MKK7 shows reduced basal kinase activity after in vitro neddylation by RanBP2ΔFG. Consistently, RanBP2 knockdown leads to reduced proliferation and impaired EMT phenotype in human breast cancer cells and the effects of RanBP2 knockdown are reversed by simultaneous MKK7 knockdown. Taken together, our data suggest that MKK7 undergoes neddylation in human breast cancer cells, which limits its basal kinase activity.

Neddylation Inhibitor MLN4924 Suppresses Cilia Formation by Modulating AKT1

Neddylation-Independent Activities of MLN4924

MLN4924: Additional Activities Beyond Neddylation Inhibition.

Blockage of Neddylation Modification Stimulates Tumor Sphere Formation in Vitro and Stem Cell Differentiation and Wound Healing in Vivo

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells

Suppression of tumor angiogenesis by targeting the protein neddylation pathway.

MLN4924, a First-in-Class NEDD8-Activating Enzyme Inhibitor, Attenuates IFN-β Production

Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways

Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway

Induction Of P21-Dependent Senescence: Role Of Nae Inhibitor Mln4924

Protein Neddylation and Its Alterations in Human Cancers for Targeted Therapy.

The Nedd8-activating Enzyme Inhibitor MLN4924 (Tak-924/Pevonedistat) Induces Apoptosis Via C-Myc-noxa Axis in Head and Neck Squamous Cell Carcinoma.

Neddylation controls basal MKK7 kinase activity in breast cancer cells

Inactivation of the Cullin (CUL)-RING E3 Ligase by the NEDD8-activating Enzyme Inhibitor MLN4924 Triggers Protective Autophagy in Cancer Cells

Targeting cullin neddylation for cancer and fibrotic diseases

Overactivated neddylation pathway as a therapeutic target in lung cancer

Suppression of Glioblastoma by Targeting the Overactivated Protein Neddylation Pathway.

The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway

Inhibiting Neddylation Modification Alters Mitochondrial Morphology and Reprograms Energy Metabolism in Cancer Cells.

Induction Of Protective Autophagy In Cancer Cells By Nae Inhibitor Mln4924